行情

SGEN

SGEN

Seattle Genetics
NASDAQ

实时行情|Nasdaq Last Sale

108.30
-0.04
-0.04%
盘后: 108.30 0 0.00% 17:26 11/11 EST
开盘
107.80
昨收
108.34
最高
108.95
最低
106.84
成交量
62.01万
成交额
--
52周最高
108.95
52周最低
51.50
市值
185.61亿
市盈率(TTM)
-57.9671
分时
5日
1月
3月
1年
5年

分析师评级

17位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SGEN 新闻

  • Week In Review: AstraZeneca Announces $1 Billion Fund For China Life Science Startups
  • Seeking Alpha - Article.1天前
  • Here's Why Seattle Genetics Stock Jumped 25.7% in October
  • MotleyFool.com.4天前
  • Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the ASH Annual Meeting
  • Business Wire.4天前
  • Buy These 2 Stocks to Access China's Huge Healthcare Market
  • MotleyFool.com.5天前

更多

所属板块

生物技术和医学研究
-0.40%
制药与医学研究
-0.41%

热门股票

名称
价格
涨跌幅

SGEN 简况

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
展开

Webull提供Seattle Genetics, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。